Ucwaningo olusha lwaseCleveland Clinic lubonisa ngokokuqala ngqa ukuthi i-ibrutinib (ibrutinib) egunyazwe yi-FDA ye-lymphoma ne-leukemia ingase futhi isize ekwelapheni izimila zobuchopho ezivame kakhulu nezibulalayo, futhi ingase ngolunye usuku isetshenziswe ezigulini ezine-glioblastoma Futhi ithuthukise amazinga okusinda.
Ngokombiko we-American Brain Tumor Association, izinga lokusinda kwe-glioblastoma liphansi kakhulu, futhi ukusinda okumaphakathi kweziguli ezithola ukwelashwa okujwayelekile kungaphansi kwezinyanga eziyi-15. I-Glioblastoma iyithumba ebuchosheni elibulala kakhulu futhi imelana kakhulu nokwelashwa kwamanje. Kunesidingo esiphuthumayo sokuhlinzeka lezi ziguli ngokwelashwa okusha ngokushesha okukhulu.
In an earlier study, Bao and colleagues found that i-glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain izicubu in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
